User login
Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).
Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.
Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.
Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.
Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242
Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).
Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.
Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.
Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.
Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242
Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).
Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.
Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.
Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.
Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242